Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Structure-based lead optimization to improve potency and selectivity of a novel tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid series of heparanase-1 inhibitor.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Imai, Yudai1 (AUTHOR); Suzuki, Ryo1 (AUTHOR); Wakasugi, Daisuke1 (AUTHOR); Matsuda, Daisuke1 (AUTHOR); Tanaka-Yamamoto, Nozomi1 (AUTHOR); Ohki, Yuta1 (AUTHOR); Mima, Masashi2 (AUTHOR); Endo, Mayumi2 (AUTHOR); Tabata, Ryotaro3 (AUTHOR); Matsuzawa, Hitomi4 (AUTHOR); Hasegawa, Yoshitaka4 (AUTHOR); Kato, Sota3 (AUTHOR); Sugisaki, Mami3 (AUTHOR); Miyagawa, Hiroh2 (AUTHOR); Fujimoto, Natsuko2 (AUTHOR); Fukunaga, Takuya2 (AUTHOR); Kato, Sayaka2 (AUTHOR); Takahashi, Teisuke3 (AUTHOR); Kakinuma, Hiroyuki1 (AUTHOR)
- Source:
Bioorganic & Medicinal Chemistry. Oct2023, Vol. 93, pN.PAG-N.PAG. 1p.
- Subject Terms:
- Additional Information
- Abstract:
[Display omitted] • Compound 2 was optimized using X-ray analysis and FMO calculation, resulting in 4e with increased potency against HPSE1. • Methylation of 6-hydroxyl group of 4e resulted in 18 with improved selecivity towards HPSE1 over GUSβ/GBA. • Compound 18 significantly suppressed serum HPSE1 activities in mice at 3, 30, and 100 mg/kg. Heparanase-1 (HPSE1) is an endo -β- d -glucuronidase that is the only mammalian enzyme known to cleave heparan sulfate (HS) of heparan sulfate proteoglycans (HSPG), a key component of the glycocalyx layer of the vascular endothelium matrix. Inhibition of HPSE1 has therapeutic potential for cancer and proteinuric kidney diseases. We previously reported that 2 showed a moderate potency as an HPSE1 inhibitor and an issue of selectivity against exo -β- d -glucuronidase (GUSβ) and glucocerebrosidase (GBA) remained. A structure-based lead optimization of 2 using X-ray co-crystal structure analysis and fragment molecular orbital calculation resulted in 4e , which showed a more than 7-fold increase in HPSE1 inhibitory activity. The subsequent introduction of a methyl group into the 6-hydroxy group of 4e resulted in 18 with reduced inhibitory activities against GUSβ and GBA while maintaining the inhibitory activity against HPSE1. The inhibitory activities of 18 against serum HPSE1 in mice were significant and lasted for 4 h at doses of 3, 30, and 100 mg/kg. Compound 18 could be a novel lead compound for HPSE1 inhibitors with improved inhibitory activity against HPSE1 and increased HPSE1 selectivity over GUSβ and GBA. [ABSTRACT FROM AUTHOR]
- Abstract:
Copyright of Bioorganic & Medicinal Chemistry is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
No Comments.